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Abstract 
 ALS one of the most common fatal neurodegenerative diseases to date among the adult 
population. Symptoms of ALS lead to the atrophy neuromuscular junctions, deterioration of 
upper and lower motor neurons in the nervous system, neuronal death, and eventually respiratory 
failure. Main genes discussed that are known to lead to ALS when mutated or disrupted include 
SOD-1, TARDBP, FUS, C9orf72. Glutamate excitotoxicity has also been linked to 
overstimulation of neurotransmitters in the brain causing complications that result in ALS. There 
are only two FDA approved drugs in the U.S. to treat symptoms ALS, one of them being the 
drug Riluzole. Since Riluzole did not go through all phases of clinical testing, due to its 
imminent need, there are still many unknowns about what effects it may have. Our experiment is 
testing for any effects of fatigue on mice by assessing their coordination and endurance after 
being administered a low (1mg/kg), moderate (5mg/kg), or high (10mg/kg) dose of Riluzole. 
Spatial memory, directional memory, recollection, and stereotypy-like movements were 
evaluated between males and females at control, low, moderate, and high dosages of Riluzole 
after i.p. injection using the Rotorod, wooden maze, and activity box apparatuses. Our hypothesis 
predicted that a higher dose of riluzole will produce more problems with spatial memory and 
recollection. When evaluating for stereotypy we predicted that females would conduct more time 
conducting repetitive movements. On the Rotorod apparatus, after our initial pilot study, we 
hypothesized that the higher dosage of Riluzole would cause the mice to have less coordination 
and therefore not run as long on the Rotorod.  
 Keywords: ALS, Riluzole, SOD-1, Spatial Memory, Directional Memory, Fatigue  
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The Behavioral Effects of Riluzole on Memory, Coordination, and Stereotypy in CD-1 Mice 
Riluzole, also known as Rilutek, was approved by the FDA in 1995 as a pharmacological 
treatment for ALS. Previous research done in our LIU laboratory examined Riluzole’s 
effectiveness for treating anxiety in mice to assess overall if Riluzole could also be used as a 
treatment for PTSD.  This opened our awareness for how Riluzole could be utilized in other off 
label therapeutic uses than its original approval for ALS. Amyotrophic lateral sclerosis (ALS) is 
a fatal disease that is the most common motor neuron disease affecting adults to date. ALS is 
also most commonly known in the US as Lou Gehrig disease in tribute to the baseball player 
who suffered from the disease in the 1930s (Bonafede & Mariotti, 2017). However, this disease 
was initially known as Charcot’s sclerosis in honor of Jean-Martin Charcot who was a 
neurobiologist and the first person to describe the disease in the 1870s (Bonafede & Mariotti, 
2017). ALS is an adult-onset fatal neurodegenerative disorder affecting neurons responsible for 
voluntary muscle movement (National Institute Of Neurological Disorders And Stroke, 2013). 
Characteristics include causing weakness in limb and bulbar muscles with atrophy, spasticity, 
weight loss, and respiratory failure (Miller et. al., 2012). It is characterized by the deterioration 
of upper and lower motor neurons of the nervous system, causing a variety of neurodegenerative 
syndromes (Schultz, 2018). Primarily, glutamatergic and cholinergic motor neurons suffer from 
continuous degradation over time. More evidence is forthcoming that suggests the accumulation 
of chronic glutamate excitotoxicity may be an important contributing factor in the neuronal death 
associated with ALS (Miller et. al., 2012). These glutamate neurons initiate important 
communication between the brain and voluntary muscles. Upper and lower motor neurons die off 
and stop sending messages to muscles which then atrophy. The loss of neuromuscular junctions 
(NMJs) play a role in the early pathological stages of ALS leading to motor neuron degeneration 
(Martineau et. al., 2018).  Some researchers have stated that there may be a denervation of NMJs 
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before any symptoms become apparent and before any noticeable cell body loss or axon loss in 
the motor neurons. In the previous research, Martineau et. al. (2018) noted there were significant 
findings detailing that some motor units (MU) degenerate and quickly lose their NMJs while 
other populations of MUs compensate through axonal sprouting and increase in size. However, 
studies show (National Institute of Neurological Disorders and Stroke, 2013). the rescue of 
neuronal loss in mice that have been specifically, genetically modified with a knock in gene does 
not necessarily improve NMJ denervation suggesting that local branch-specific events may play 
a key role in NMJ denervation (Martineau et. al., 2018).  Martineau et. al. (2018) revealed that 
the larger the arborization or branching out of the axon, the more vulnerable the neuron becomes 
because of the amount of energy it needs to continue functioning from an already deteriorating 
structure and thus causing more stress on the progression of the disease. However, while 
originally only recognized by the diseased motor cortex and spinal cord pathology, much ALS 
research has been published recognizing that it is a multisystem condition with effects that 
extend to the frontotemporal, subcortical, and cerebellar regions as well (National Institute of 
Neurological Disorders and Stroke, 2013).  Memory issues have gone extremely 
underrecognized until recent studies have demonstrated that there are deficits that can occur 
during the progression of ALS (Christidi et. al., 2019).  Therefore, this thesis not only evaluates 
the effectiveness of Riluzole on motor coordination and endurance, but also on memory.  
To give the reader some background information, ALS is divided into two categories: 
sporadic ALS (sALS) and familial/genetic ALS (fALS) (National Institute Of Neurological 
Disorders And Stroke, 2013).  Sporadic ALS occurs at random with no clear risk factors and no 
apparent genetic links and makes up the majority (90% or more) of ALS cases. Familial ALS is 
only found in about 5-10% of cases and is derived from a parental gene. Some epidemiological 
risk factors may include age, gender, andrace/ethnicity. The typical age of onset for ALS 
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development has been observed between 50 and 75 years of age) (National Institute Of 
Neurological Disorders And Stroke, 2013): Bonafede & Mariotti, 2017). Men are slightly more 
at risk of developing ALS than females, just as Caucasians and Hispanics are found more likely 
to develop ALS. Also, military veterans are suggested to be 1.5 to 2 times more likely to develop 
ALS presumed from exposure to environmental toxins. Early symptoms of ALS can include 
muscle twitches (in arms, legs, shoulders, or tongue), muscle cramps, spasticity of muscles, 
muscle weakness (in arm, leg, neck, or diaphragm), slurred/nasal speech, and difficulty chewing 
or swallowing. If symptoms begin in the arms or legs, it is known as “limb onset” ALS whereas 
if problems first occur with speech or swallowing it is referred to as “bulbar onset” ALS 
(National Institute Of Neurological Disorders And Stroke, 2013).  These symptoms vary because 
the disease progression varies from person to person, but generally people with ALS retain their 
cognitive processing and awareness but lose muscular function. This can lead to further issues 
such as anxiety and depression as a result (National Institute Of Neurological Disorders And 
Stroke, 2013). The main cause of death in ALS cases is ultimately respiratory failure (Zarei et. 
al., 2015).   In the very end stages of ALS, most patients are forced to resort to tracheostomy 
delivered ventilation because they have reached a state of motor paralysis of all voluntary 
muscles that does not allow them to breathe on their own any longer (Zarei et. al., 2015). 
Electromyography (EMG), nerve conduction study (NCS), and magnetic resonance 
imaging (MRI) tests are common muscle and imaging tests to evaluate nerves, muscles, and 
images of the brain and spinal cord. Other functional scales such as “ALS Functional Rating 
Scale-Revised (ALFRS-R)”, forced vital capacity, and muscular testing are used to assess the 
motor functioning in patients with ALS.  Blood and urine samples are common laboratory tests 
ordered to rule out other diseases however there remains a number of diseases that can resemble 
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ALS, which is also why it is a good idea to gain a second neurological opinion (National Institute 
Of Neurological Disorders And Stroke, 2013).  
The symptoms of this progressive disease worsen over time as there is currently no cure. 
However, Riluzole (Rilutek) and edaravone (Radicava) are FDA approved drugs that help 
manage symptoms but do not reverse the damage already done to motor neurons (National 
Institute Of Neurological Disorders And Stroke, 2013). Other than these two drugs, the only 
other options involve symptom management such as physical therapy for muscle mobility, 
speech therapy to try to keep the ability to communicate, and nutritional support to manage 
weight loss that makes them weaker and avoid foods difficult to swallow. When ALS worsens, 
breathing support through noninvasive ventilation or mechanical ventilation (respirators or 
tracheostomy) may be needed (National Institute Of Neurological Disorders And Stroke, 2013).  
Effecting roughly 14,000-15,000 Americans alone, death caused by ALS generally occurs 3 to 5 
years after symptom onset (National Institute Of Neurological Disorders And Stroke, 2013) 
however, the course of the disease varies based on the individual. For example, half of all ALS 
patients die within thirty months of their symptoms onset whereas twenty percent may live 
another 5-10 years (Schultz, 2018). 
Dozens of gene mutations have been found that may be the inherited alleles, but (Butti & 
Patten, 2019) 25-40% of familial cases are from the defect in the chromosome 9 open reading 
frame 72 gene (C9ORF72) (Ingre et. al., 2015) As shown in Table 1 (Butti & Patten, 2019) some 
of the most likely causal ALS genes include are superoxide dismutase (SOD1),  Tar-DNA 
Response Binding protein (TARDBP/TDP-43), fused in sarcoma (FUS), and a hexanucleotide 
expansion repeat in Chromosome 9 Open Reading Frame 72 (C9ORF72). Important research 
was done by Dervishi et. al., (2018) to try to expand developments in the field of human genetics 
by linking genes with proteins and protein interaction networks to find their cellular balances in 
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order to determine at what point they become disturbed enough to cause a mutation (Dervishi et. 
al., 2018). Finding this point where cellular homeostasis is disrupted may be an underlying factor 
for neuronal vulnerability explaining when and why a neuron lacks its ability to perform a key 
function(s). In Dervishi et. al. (2018) studies, the authors researched ALS by focusing on the 
corticospinal and spinal motor neuron populations that are known to degenerate with the disease.  
Currently, 147 different mutations are recognized in ALS patient cases- 39 are accepted 
to have a strong correlation to causation and 108 are thought to be associated with ALS by 
possibly increasing the chances of development (Dervishi et. al., 2018). Even if the genes 
initially appear unrelated, many are within the same cellular pathways (ex. axonal transport 
defects, unfolded protein response, endoplasmic reticulum (ER) stress) so they are likely 
important to create proper functioning in the motor neuron circuitry and thus understanding their 
relationships can help maintain proper health through future therapeutic targets. Dervishi et. al., 
(2018) created a list of mutated genes associated with ALS and the proteins that bind to them to 
further investigate which canonical pathways they are involved in, their interaction, and which 
cellular events they effect to dysregulate and regulate homeostasis (Dervishi et. al., 2018) For 
example, Dervishi et.al. (2018) published that PPARG and PPARGCIA are two important 
proteins in lipid biosynthesis and were upregulated in the Betz cells of sALS (sporadic ALS) and 
patients with TDP43 pathology. This is significant because lipid metabolism has been found to 
be altered and remodeled in both cortexes of mice and cerebrospinal fluid of humans with ALS 
and mutations disrupting lipid homeostasis may have a role in ALS neuronal vulnerability 
(Dervishi et. al., 2018). This also applies to the thyroid hormone receptor and RXR activation 
modulating lipid metabolism and DHA (docosahexaenoic acid) which is important to “initiation 
and modulation of survival signaling (Dervishi et. al., 2018, p.14)” but hurts neuronal survival 
when disruption occurs from fatty acid deficiency. In addition, the accumulation of certain 
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proteins in the ER cause ER-stress which in turn is a leading cause of neurodegeneration and 
activates UPR (unfolded protein response) to try and restore ER homeostasis. “ALS proteins are 
indeed actively involved to ensure that the protein folding and turn-over is properly controlled 
(Dervishi et. al., 2018, p.15).” “Many of the ALS proteins are actively involved in canonical 
pathways that are responsible for maintaining cyto-architectural homeostasis (Dervishi et. al., 
2018, p.15)” In cases of ALS, maintaining the structure of DNA is extremely important and a lot 
of emphasis is placed on the canonical pathways that will ensure DNA stability (Dervishi et. al., 
2018). The p53 tumor suppressor protein is a major response to DNA damage as the activation of 
it causes gene expression to improve DNA integrity (Dervishi et. al., 2018). Things such as 
double stranded breaks and problems with 14-3-3 proteins- which showed a high significance of 
signaling events in this study- cause issues with DNA stability (Dervishi et. al., 2018). Growth 
factors such as the hormones VEGF, NGF, IGF-1, HGF, EGF, PDGF, FGF, and CNTF signaling 
are important in ALS because motor neurons require growth hormone for survival and health just 
like any other bodily neurons and are crucial to maintain homeostasis (Dervishi et. al., 2018). 
This study identified that YWAHZ (14-3-3 protein zeta), when reduced, causes an increase to ER 
stress- which we already know disrupts homeostasis- which suggests having high levels of 
YWAHZ is important for neuronal survival in many different neurodegenerative diseases 
because of the effect on ion channels’ functioning, promoting UPS (ubiquitin-proteasome 
system: a key canonical pathway in promoting protein degradation), and protein trafficking from 
the ER (Dervishi et. al., 2018). YWHAZ levels in the Betz cells of patients with sALS and ALS 
patients with TDP43 pathology are found to be greatly reduced. ZFYVE27 (Protrudin) is 
important to maintain homeostasis in the ER as well in addition to oxidative stress and proper 
transport of molecules and ions, particularly K+ and Ca+2 by being an adaptor within neurons 
with protein and lipid binding (Dervishi et. al., 2018). An impairment in this can lead to 
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degeneration in motor neurons and has already been associated with ALS, because of 
accumulation and restriction in distinct regions of Betz cell soma of patients, and several other 
diseases affecting motor function (Dervishi et. al., 2018). Sometimes the accumulation of 
proteins in general with TDP43 and their depletion in the cytoplasm may not require any 
mutation but simply cause neurodegeneration because they lose their ability to function from 
being trapped in aggregates. These are some of the underlying cellular mechanisms that need to 
be understood in the Betz cells of ALS patients to find the imbalances that contribute to neuronal 
vulnerability an degeneration not just in ALS, but across a variety of motor neuron diseases. 
Further research is needed to understand these protein interactions, but these protein bases can 
contribute to significant mutations and circuitry system changes (Dervishi et. al., 2018).  
Some of the first studies of Riluzole were done on SOD1 mice, leading our laboratory to 
investigate Riluzole’s use with genetically modified mice. In reference to Table 1, the SOD1 
gene is a very important aspect of this disease and the many mutations of it have been linked to 
causing ALS, even though definitively unknown, there is significant information that it includes 
the SOD1 gene. It was mutations in the SOD1 gene that were the first to be an identifiable factor 
across many ALS cases, often found in about 20% of familial cases and up to 4% of sporadic 
cases (Bonafede & Mariotti, 2017). To date, scientists have seen over 150 mutations involving 
this gene, often inherited in a dominant manner except the D90A mutation, the most common 
mutation, which can also be inherited recessively (Ingre et. al., 2015). In addition this gene has 
been linked through many other motor neuron diseases. “Mutations in CU/Zn superoxide 
dismutase 1 (SOD1) lead to Amyotrophic Lateral Sclerosis (ALS) (Baskoylu et. al., 2018, p.1)” 
which affects glutamatergic and cholinergic motor neurons. “Soluble SOD1 oligomers are 
considered the most toxic species and play a key role in the pathologic process of ALS (Dong 
et.al., 2018, p.413)” including general SOD 1 mutational consequences and causing changes in 
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the processing and metabolism of RNA molecules.  SOD enzymes are also critical in cells 
exposed to oxygen by acting as an antioxidant defense (Bonfede & Mariotti, 2017). A study 
created by Baskoylu et. al. (2018), created the first “C. elegans knock-in/single-copy models for 
SOD1 ALS by directly editing the C.elegans sod-1 gene to recreate SOD1 amino acid changes 
that cause ALS in patients (Baskoylu et. al., 2018, p.2)” through new genome editing techniques. 
They identified that both the loss and gain of the sod-1 functioning contributes to 
neurodegeneration but affects the degeneration of the cholinergic and glutamatergic neurons 
differently- that the mechanisms driving degermation need to be considered as not identical. 
Both the cholinergic and glutamatergic neurons were hypersensitive to oxidative stress and lead 
to motor neuron loss in the single-copy/knock in animals and overexpression model animals, 
although it is still unclear why this is the case. There are two ideas as to why this may happen 
including that oxidative stress may induce premature aging impacting the patient during mid-life 
stages, and secondly, mutant ALS SOD1 may impair oxidative stress response by antagonizing 
normal SOD1 function (Baskoylu et. al., 2018). High levels of ALS SOD1 proteins have been 
shown to have “toxic gain of function properties (Baskoylu et. al., 2018, p.2),” as opposed to a 
loss of some functioning, and in turn leads to these deleterious effects (Baskoylu et. al., 
2018).Through C. elegans studies, their work showed, single-copy/knock-in sod-1 models after 
oxidative stress was that a decrease in sod-1 functioning caused neuron deterioration and motor 
neuron loss in glutamatergic neurons whereas the gain of sod-1 function contributed to 
cholinergic neuron degeneration. Something interesting they also found was that dopaminergic 
and serotonergic neurons did not show neurodegeneration even under the same oxidative stress 
conditions (Baskoylu et. al., 2018).  
TARDBP gene is located on Chromosome 1 and is what codes for the protein TDP-43, 
which is what can suffer from mutations leading to ALS (Ingre et. al., 2015). This protein’s 
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significance lies in its involvement of DNA and RNA binding processes. Regarding RNA, the 
TDP-43 protein will be involved in transcription of RNA as well as splicing and maintenance for 
RNA stability and subcellular RNA transport (Ingre et. al., 2015), and stress granule assembly. 
This protein has also started to be studied for its role in regulating other genes involved in 
synaptic formation and neurotransmitter processes. Mutations, over 30 identified, of this protein 
are not as common since they have only been recognized in about 5% of familial ALS patients 
and 1 % of sporadic ALS patients (Ingre et. al., 2015). TDP-43 mutation often leads to 
phosphorylation (the introduction of a phosphate group to a molecule which has a significant role 
in cellular processes, signal transduction, protein regulation, etc.) which decreases the rate in 
which TDP-43 can turnover. This leads to mis-localization from its usual position in the nucleus 
to the cytoplasm and also causes the excessive buildup of proteins. In previous studies done with 
C. elegans (Caenorhabditis elegans = a nematode species) models, this has been linked to 
neuronal loss and function impairment (Bartoletti et. al., ). It is believed that “TDP-43 
aggregation leads to a gain of toxicity and its nuclear depletion results to a loss of function in 
TDP-43 (Butti and Patten, 2019, p.2).” TDP-43 is believed to be linked to several other proteins 
that can be implicated in ALS and also may be a major component of other neurodegenerative 
conditions because of its ability to bind to mRNA and regulate several other proteins such as 
FUS, Tau, ATXN 2, and progranulin (Butti & Patten, 2019). Interestingly, prolonged stress has 
been studied as a potential in promoting binding of TDP-43 to mRNA in stress granules which 
can lead to ALS progression because of inhibiting translation of the mRNA.  
 FUS is another type of DNA/RNA-binding protein, like TDP-43, that plays many roles 
within RNA processing when it is able to bind directly to RNA and has been commonly seen 
binding RNA in various cell lines and brain tissue (Bartoletti et. al., 2019). FUS also plays an 
essential role in neuronal maintenance and survival through regulation in RNA splicing. When 
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mutated, it can lead to impaired neuronal activity and synaptic deficits by suppressing local 
axonal protein synthesis leading to an integrated stress response in the hippocampus (Butti & 
Patten, 2019). These mutations have also been found to provoke motor and cognitive deficits that 
are already typical with the progression of age in an individual. For example, Bartoletti et. al. 
(2019) noticed an “inhibition of local translation in sciatic nerves (p.8219)” from the increase in 
mutant FUS accumulating in the axons in a study prior to any development of the ALS disease 
but was later attributed because of affecting motor functioning and age-dependent 
neurodegeneration.  
The C9orf72 gene located on chromosome 9, more specifically it’s GGGGCC 
hexanucleotide repeat expansion in the first promoter region, is one of the newest discoveries in 
causes of ALS as of 2011 (Butti & Patten, 2019). It has been found in about 50% of familial 
ALS cases and about 5-10% of sporadic ALS cases. In cases of ALS, patients can have repeats 
of this sequence in the thousands in comparison to the 2-30 normal repetitions demonstrated in 
control populations (Ingre et. al., 2015). The definite function of this gene is still unclear which 
is why it is difficult for researchers to determine if this repeat expansion is causing a toxic gain 
of function or loss of function, or both, leading to neurodegeneration. What researchers have 
uncovered so far is that this repeat expansion can lead to an accumulation of “repeat-containing 
RNA foci (Butti & Patten, 2019, p.6)” in tissues leading to a mislocalization and interference in 
functioning of RNA binding proteins. This is because the RNA-foci help facilitate the 
recruitment of RNA binding proteins so these mutated repeats in these coding processes cause 
alterations to how the RNA foci bind to the RNA binding proteins which alter, through 
overaccumulation, the overall metabolic functioning of the RNA.  However, scientists have also 
found that the absence, or suppression, of transcripts with this RNA-foci repeat, below normal 
control levels, disrupt protein functioning and cause various misprocessing of RNA (Butti & 
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Patten, 2019). Additionally, repetition in the C9orf72 locus can cause either a formation or 
disassembly of stress granules. This is dangerous because much research about cell culture to 
date has shown that forced oligomerization (interaction of more than one polypeptide chain or 
converting a monomer into an oligomer) of stress granules is toxic to cells (Bartoletti et. al. 
2019).  
Figure 1 shows some of the biological processes affected by these main genes previously 
discussed, but there are many other genetic contributions, mutations, and problems that can be 
attributed to ALS as there is no single gene that is causative of this neurodegenerative disease. 
For example neuroinflammation is prevalent amongst ALS as well as many other 
neurodegenerative disorders. Neuroinflammation is when there is neural injury when the brain is 
infiltrated by activated microglia, astrogliosis, and immune cells causing deregulation to 
neuronal homeostasis and survival through disrupting delicate communication between 
motoneurons and glial cells. Mutant glial cells are often causes of motoneuron degeneration 
where the interaction between microglia and motoneurons is initially supposed to protect neurons 
and can cause astrocytes to release misfolded proteins as the degeneration worsens. The 
microglial cells go from an anti-inflammatory to pro-inflammatory which makes them no longer 
neuroprotective, but neurotoxic (Bonafede & Mariotti, 2017). Another example of other possible 
contributions to ALS that are very common is glutamate excitotoxicity. Glutamate in a normal 
neurotransmission process is synthesized in the presynaptic terminal, released to the synaptic 
cleft, and leads to the activation of post-synaptic receptors going through this constant cycle of 
release and removal to maintain a balanced concentration through neuronal cells. An increase of 
extracellular glutamate and overstimulation of the receptors induces excitotoxic neuronal 
degeneration, specifically in the motor cortex and spinal cord of ALS patients (Zarei et. al., 
2015). Too much glutamate production can also lead to neurodegeneration through subprocesses 
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through activating calcium dependent enzymatic pathways increasing the influx of calcium, 
potassium, and free radicals coming in beyond levels for normal functioning. Risk factors for 
ALS are not biologically and genetically inclusive, as there have also been environmental factors 
associated with a higher risk for developing ALS. The inflammation, oxidative stress, and 
neurotoxicity of heavy metals that come from smoking are noted as a risk factor to increase the 
probability of ALS, especially for those who begin smoking at a younger age. This makes sense 
compared to research that associates ALS with exposure to certain chemicals and metals. 
Agricultural chemicals such as pesticides, fertilizers, herbicides, insecticides, and formaldehyde 
exposure over more than a four yr period could be at an increased risk for ALS. Finally, 
interesting studies have been investigating athletes who may also have a higher ALS risk because 
of genes related to exercise but these results, to date, are not the most consistent yet.   
Looking at ALS from a more psychological perspective, other studies have been done 
using the Frontal Systems Behavioral Scale (FrSBe) to assess behavioral changes in aspects such 
as apathy, disinhibition, and executive dysfunction throughout ALS. This is both to assess the 
usefulness of this system for assessment of ALS in general and to establish whether or not there 
is a connection with behavioral changes in patients to damage in the frontal lobe system. Most 
often, from what researchers have seen in ALS cases thus far, is that patients lose muscle 
function and exhibit states of paralysis but much is still unknown about what happens to a 
patient’s state of consciousness and psychological functioning (Grossman et. al., 2007). Up to 
this point it appears that ALS can induce some memory deficits but that patients overall remain 
aware and psychologically active throughout the progression of the disease. This scale is broken 
into two forms- Self Rating form and Family Rating form to compare a patient’s current 
behavior to their behaviors before their diagnosis or onset of symptoms. Previous studies have 
marked patient’s behavioral changes to be characterized by “decreased initiation of 
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conversations, a lack of motivation to participate in activities, or decreased agreeableness with 
lowered frustration tolerance (Grossman et. al., 2007, p.56)” as well as not understanding or 
caring for the feelings of others. Results showed the Family Rating saw “neurobehavioral 
symptoms associated with ALS (Grossman et. al., 2007, p.59)” upon completing the FrSBe- 
which can be easily scored and requires no medical training to use or assess. Caregivers also 
completed rating scales that showed significant elevated neurobehavioral changes from pre and 
post illness, mostly in apathy, suggesting it was due to underlying neurodegeneration. These 
behaviors before an official diagnosis of ALS demonstrate a distinct personality profile for ALS 
patients. In addition, this study concluded that “post-illness Apathy scores on the FrSBe 
significantly predicted performance in verbal fluency tests (Grossman et. al., 2007, p.59).”  
Verbal fluency is commonly known to be affected in the progression of ALS, thus 
suggesting even more of a link between behavioral disturbances- that characterize FTD- and 
ALS. Grossman et. al. (2007) caution that these observances of verbal performance have not 
been evaluated for being affected by outside sources such as medication side effects, fatigue, or 
respiratory fatigue, for example. Another interesting distinction in their research reports that the 
type of ALS- bulbar vs. limb onset- showed impact on post-illness ratings. Bulbar-onset ALS 
were more likely to develop behavioral symptoms, more significantly those of apathy. There are 
some concerns to be considered along with this study including the sample size being small, 
possible lack of protocols being identical between the psychological screening procedures and 
neuropsychological testing, and that the sample chosen may be higher functioning patients by 
excluding those unable to speak (Grossman et. al., 2007). There may be bias to ALS patients 
who also display dysarthria because of the possible difficulty for family/caregivers to distinguish 
rating behaviors without impact of symptoms. For example, just because a patient has difficulty 
communicating does not mean they did not engage with people or show more severe apathy. 
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Overall, Grossman et. al. (2007) research shows not just a gain for understanding ALS pathology 
but for granting understanding to the families and caregivers as well whom this disease also 
affects. They reported “families have appreciated being told about the behavioral changes and 
their potential effect on interpersonal relationships (Grossman et. al., 2007, p.60).” It brings a 
shred of understanding and reasoning to a very perplexing chain of events brought on by this 
disease (Grossman et. al., 2007). The article containing this information from Grossman et. al. 
(2007) is speaking purely to the psychological effects of ALS on patients and those around them, 
which is not found in much research across the spectrum but is important to the overall effect of 
this disease to everyone involved. 
Methods for diagnosing ALS were briefly stated with mention of EMGs, NCS, and 
MRIs, however, due to the complex and multifaceted nature of ALS- early and accurate 
diagnosis is extremely difficult. It is usually not until up to 18 months after the onset of a 
patient’s symptoms and extreme exclusion of any other possible medical complications that 
could be causing the symptoms that there is a confirmed diagnosis of ALS (Zarei et. al., 2015). 
The pathogenesis of ALS can be easily misdiagnosed because many of the biological factors and 
physical symptoms also overlap with other neurodegenerative diseases. For example there are a 
lot of correlations and studies comparing ALS with the FTD (frontotemporal dementia), that 
makes it difficult to give a diagnosis with certainty (Zarei et. al., 2015). This is why the El 
Escorial criteria ( established 1994) was published by the World Federation of Neurology and 
revised criteria renamed Airlie House Criteria (established 1998) were established as a set of 
inclusion standards for diagnosing ALS to a degree of certainty and for the purpose of entering 
clinical trials and research (Zarei et. al., 2015). In the year 2000, there were further 
neurophysiological measurements introduced, using what is known as the Awaji algorithm, 
which takes into account electromyogram and clinical abnormalities to minimize false positives. 
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However, it should be taken into consideration that none of these methods or criteria take into 
account the mental and behavioral differentiations between individual patients. Ultimately, 
consistently over the years a diagnosis for ALS requires evidence of degeneration in lower and 
upper motor neurons as well a progression of neurological symptoms that spread to other 
anatomical regions (Zarei et. al., 2015).  
 ALS is a difficult disease to experience as a patient, loved one, and doctor due to the lack 
of current treatment from the overall complex pathogenesis of the disease. To date, there is no 
cure. There are treatments and therapeutic approaches to try an alleviate symptoms produced by 
the disease but even these are not at a very significant level to improve quality of life for ALS 
patients. Up until the 1990’s there were only methods of pain management such as physical 
therapy for muscle mobility, speech therapy to try to keep the ability to communicate, and 
nutritional support to manage weight loss that makes them weaker and avoid foods difficult to 
swallow (National Institute Of Neurological Disorders And Stroke, 2013). And today, as more 
biological and genetic factors come to light, research is underway for gene and stem cell 
therapies. Other treatments like Masitinib, although not currently approved by the FDA, stops 
enzymes involved in inflammation which is significant since nerve inflammation is a common 
aspect of ALS. Mastinib has been proven effective when in combination with Riluzole (Scott, 
2017). Tirasemtiv is another possible treatment, not currently approved by the FDA, that 
activates muscle tissue and has been shown to help ALS patients breathe (Scott, 2017). There is a 
large hope for combination drug therapies to halt ALS altogether through the joining of multiple 
targeted drug effects added together. One researcher states that ALS treatments need to be 
considered on a more personal treatment basis because, while the cause of ALS is unclear, it is 
most likely heterogeneous and varies patient to patient. Molecular genetics (“use of DNA and 
RNA sequencing to pinpoint the genes and mutations associated with disease (Scott, 2017, 
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p.120)”) is one mode being explored for a cure by switching certain genes on and off. Antisense 
therapy has been researched, using small sections of DNA, RNA, and other oligonucleotides- 
they are trying to block the proteins associated with ALS from producing by binding these 
sections to specific RNA copies of genes that turn off the targeted protein’s ability to produce 
(Scott, 2017). The previously mentioned Superoxide dismutase (SOD) (over 100 mutations 
implicated in ALS) and C9ORF72 (protein in brain cells) are now two targets for antisense 
therapy because of their prominent involvement in features of ALS. Gene therapy- replacing 
faulty genes with new copies- is being tried as a more permanent fix however, by not knowing 
what causes ALS, it causes problems finding which genes to add (Bonafede & Mariotti, 2017). 
Plus, research suggesting that problems in glial cells may be involved in motor neuron death 
leads to the belief that modifying genes in glial cells surrounding and supporting motor neurons 
may help restore their function through gene therapy. A second longterm fix being investigated 
is stem-cell therapy to multiply a variety of cells that keep motor neurons functioning and 
healthy. Mesenchymal stromal cells are being explored for this treatment route because they are 
isolated from adipose tissue containing cells that secrete proteins helping to support motor 
neuron survival and the immune system (Bonafede & Mariotti, 2017). FDA approved trials for 
gene and stem-cell therapy were approved to begin Phase I in late 2016 and the hope is high for 
results. However, pharmacologically, there are only two FDA approved disease modifying 
treatments including Riluzole and edaravone. As chemically shown in Figure 2, Riluzole, also 
known as Rilutek, was approved by the FDA in 1995 and originally developed by a French 
company known as Rhone-Poulenc Rorer (Flavell, 2013) with the original intent for use as an 
antiepileptic medium. Edavarone was developed in Japan in 2015 to slow the progression of 
ALS and in 2017 was the first drug in 20 years (since Riluzole) to be approved by the FDA. It is 
BEHAVIORAL EFFECTS OF RILUZOLE 
 
20 
an anti-oxidant molecule that was usually used to treat stroke but was found to significantly slow 
symptom progression in early stages of ALS (Scott, 2017). 
Riluzole has been regarded as the most effective pharmacologic for those with more 
advanced ALS. It has been noted for its ability to inhibit glutamate release from presynaptic 
terminals and limit glutamate excitotoxicity by blocking voltage-gated sodium channels 
(Bonafede & Mariotti, 2019). Riluzole also exhibits many other neuroprotective factors that slow 
neurodegeneration and slightly improving motor performance but the reasons why, beyond its 
effects of protecting motoneuron cells from glutamate stress, are unknown. This medication has 
been known to delay the need for assisted breathing or having a tracheostomy, and even delaying 
eventual fatalities in patients by 2 to 3 months.  However, this drug is usually recommended for 
patients with a prognosis of over five years due to the limited effectiveness. Riluzole is one of 
the very few treatments approved for ALS in most countries although it has been called into 
question for its clinical use because of the high cost and modest efficacy (Miller et. el., 2012).  
Due to the lack of other more effective treatment methods at the time Riluzole was made 
available to the public, it was fast tracked through several stages of research and further trials 
because of the imminent need. This makes it a key drug of many research studies involving ALS 
in order to go back and evaluate how effective Riluzole truly is in addition to any alternative 
effects that may result from use of this medication that have come up over its usage through the 
years. Additionally, heavy research is being done to assess the positive factors of Riluzole and 
see if they could be beneficial to other neurodegenerative and neurological diseases.  
In terms of determining the most effective way to administer Riluzole for the most 
significant results, Dyer and Smith (2016) aimed to evaluate the pharmaceutical attributes of 
Riluzole by describing benefits, limitations, and risks associated with the different forms of 
administration. Tablets were the first form of Riluzole made readily available and approved by 
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the FDA however, this may not be practical for all patients with ALS because of the common 
development of dysphagia. Dyer and Smith (2016) explain how this leads caregivers to try and 
crush tablets to aid in ingestion but, this can increase the likelihood of errors such as incorrect 
dosing, changes in the drug’s performance, product instability, impact on absorption 
characteristics/ reaching the absorption site, and irritating or anesthetic effects causing an 
unpleasant mouthfeel. Recently an oral liquid solution of Riluzole is approved and readily 
available. The oral liquid formula is comprised of finely divided particles of the drug substance 
suspended in a thixotropic vehicle and given through an oral dosing syringe for more accurate 
dosing and no compromise on the drug’s effectiveness (Dyer & Smith, 2016). Being an aqueous 
vehicle, its design minimizes the anesthetic effect and odd metallic taste in the mouth. For every 
1mL of Riluzole oral suspension there is 5 mg of active drug- so you can reach the typical 
100mg dose with 10mL (=50mg) twice a day. An ideal pharmaceutical suspension has a high 
viscosity with low rates of shear so that the particles settle very slowly or remain permanently 
suspended while in storage (Dyer & Smith, 2016). This article also gives a lot of insight to the 
general properties of Riluzole such as how it is a lipophilic drug substance with a low aqueous 
solubility. Riluzole is slightly soluble in water at a neutral pH although the chemical stability 
decreases significantly under acidic conditions. When Riluzole is absorbed after oral 
administration, it happens rapidly with maximal plasma concentrations occurring within 60-90 
minutes. However, it should be noted that the rate and extent of absorption is reduced when 
Riluzole is given with high-fat meals (Dyer & Smith, 2016).  
Umemiya and Berger (1995) investigated synaptic modulation by Riluzole in hypoglossal 
motoneurones because of the benefit the drug has been known to have in motor neuron diseases, 
such as ALS but it effects on singular motoneurones still being unclear. Riluzole has been 
regarded as both an anticonvulsant and neuroprotective compound that lead to these positive 
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effects. It has been seen to suppress voltage-activated sodium channels expressed in various 
neuronal systems. Since these sodium currents are essential for neuronal excitation, Riluzole has 
been seen stabilizing these neurons and suppressing evoked glutamate release in the central 
nervous system (CNS) (Umemiya & Berger, 1995). This leads to positive effects since an excess 
release of glutamate from receptors can cause neuronal degeneration. In Umemiya and Berger’s 
(1995) study, brainstem slices were utilized and glycinergic inhibitory postsynaptic currents were 
evoked through electrical stimulation to visually identify the hypoglossal motoneurones. 
Riluzole was able to inhibit the mean amplitude of the glycinergic inhibitory postsynaptic 
currents by 87% and suppressed sodium currents in interneurons by 23.8% but did not modulate 
any currents activated by the voltage through calcium channels. However, Umemiya and Berger 
(1995) found that Riluzole also prevents any spontaneous transmitter release in the presence of 
tetrodotoxin (TTX) which indicates Riluzole restrains the transmitter release through 
mechanisms unrelated to inhibiting voltage-activated sodium channels. Thus, the reductions in 
spontaneous transmitter release are not due to an action on postsynaptic glycine receptors by 
deduction; Riluzole causes it presynaptically (Umemiya & Berger, 1995). With these findings in 
mind, Umemiya and Berger speculate the possibility that a reduction in glycerine release may 
cause a reduction in NMDA (N-Methyl-D-aspartic acid) receptor channel activity and Riluzole 
could slow this motorneurone glutamate excitotoxicity.  
Likewise, Miller et. al. conducted a study published in 2012 with the objective to 
examine Riluzole’s efficacy in prolonging survival through the delay of mechanical ventilation 
and a tracheostomy. The studies were randomized controlled trials with adult participants (974 
Riluzole treated patients, 503 placebo treated who have been diagnosed with ALS (prior to 5 
years). Miller et. al. (2012) study measured two outcomes: the hazard ratio of tracheostomy-free 
survival over four trials with 100 mg of Riluzole as well as the mortality percentage, 
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neurological functioning, muscle strength, and other adverse effects at Riluzole at 50, 100, and 
200 mg dosages. Miller et. al. concluded that 100 mg of the drug Riluzole prolonged median 
survival from a tracheostomy for people with ALS across the four trials by two to three months 
longer than participants taking the placebo. Although these effects of survival were small, they 
were still regarded as statistically significant results. A small benefit was found by Miller et. al. 
effecting bulbar and limb function after using Riluzole but, no improvements regarding muscle 
strength. In addition, the adverse effects from Riluzole were found to be relatively minor and 
mostly reversible when the drug was stopped. The most frequent side effects logged were nausea 
and asthenia but liver function should also be closely monitored because of alternations that can 
occur while taking Riluzole. The authors concludes with ideas for further research/trials 
examining older patients more severely affected by ALS to younger, more mildly affected 
patients (Miller et. al.).  
Schultz (2018) had reported the mechanism of action of Riluzole in his research.  He 
stated that Riluzole may inhibit glutamate excitotoxicity which may be a prominent contributor 
to the development of ALS.  Schultz’s laboratory (2018) performed a meta-analysis of Riluzole 
based on two international, placebo-controlled, double blind, matched group trials totaling 1114 
human patients with probable or definite ALS for less than 5 years, and forced vital capacity of 
60% where the subject was given a placebo, 50, 100, or 200 mg. of Riluzole split between two 
doses daily. Riluzole improved survival in both studies but showed no significance in preserving 
muscle strength or neurological function (Shultz, 2018). Overall, Riluzole was well tolerated 
among subjects but, asthenia, nausea, dizziness, decreased lung function, abdominal pain, and 
elevated alanine aminotransferase (ALT) were prominently reported among patients taking this 
medication. Shultz found that orally-administered Riluzole dosed at 100mg per day, divided into 
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two doses of 50mg had a higher efficacy when evaluating the management of adverse side 
effects.  
Further research from Sasaki-Hamada et. al. (2013) conducted a study that showed 
Riluzole did not affect behavioral effects like spontaneous alternation performance whereas 
diazepam decreased it when rats were tested in a Y-maze. They were looking to see if similar 
effects, where Riluzole has no negative effect but diazepam does, will arise in their present 
study. Riluzole was investigated in two ways by Sasaki-Hamada et. al. using the CA1 region of 
hippocampal slices in rats to compare the effects of LTP and LTD (long-term depression) and 
testing effects of mnemonic processes in the Morris water maze (MWM). The rat hippocampal 
slices were analyzed by inducing high frequency stimulation for LTP and introducing low 
frequency stimulation for LTD to examine extracellular field EPSPs. The slices were pretreated 
for 10 minutes and the solution for the experiments were the drugs dissolved in water and added 
to the perfusing solution (0.01% dimethyl sulfoxide). Riluzole at 1 and 5 M did not have an 
effect on LTP or LTD but both were impaired by 1 M of diazepam. Prior to slicing the brains of 
their subjects, they used the MWM test where the rats were assessed for 3 consecutive days with 
3 trials per day and a 15 min interval between each trial in the MWM. The rats were placed in a 
quadrant of the maze and had to swim to the platform submerged in the center as their latency 
was recorded up to 120 seconds. When they found the platform they were allowed to stay on it 
for 10 seconds whereas if they did not find it within the 120 seconds, they were guided to it and 
then allowed to stay on it for 10 seconds. Two doses of Riluzole were recorded- 3 and 10mg/kg- 
and one dose of diazepam- 10mg/kg- for the experiment and both were given 60 minutes before 
testing. Diazepam did increase the escape latency and path length days 1-3 and increased their 
swimming speed on day 3, showing no consequence to the motor deficits unlike the learning 
deficits, such as directional memory in the MWM. Riluzole, at both doses, did not affect any 
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aspect of spatial learning through escape latency, path-length, or swimming speed on any of the 
days thus, it shows hippocampal synaptic plasticity was not changed on Riluzole. In conclusion, 
Riluzole did not produce any amnesia at the same levels that cause the anxiety reducing effects. 
This was an important notation because Sasaki-Hamada et. al. found that drugs like diazepam, a 
popular drug, do produce these side effects meaning we need a better method of treatment. This 
study evaluates several effects, but heavily assesses amnesia and spatial memory which can be 
tied into what we were investigating with effects on memory and fatigue that could result from 
Riluzole (Sasaki-Hamada et. al., 2013). 
 Another study done by Zarate et. al. (2004) determined if the drug Riluzole, a common 
treatment used for ALS, had any effect on patients with recurring major depression- to see if the 
use of this drug could be expanded. This idea started because general mental health research 
shows the glutamatergic system being involved in the pathophysiology and treatment of 
depression and regulating neuronal plasticity and cellular resilience in other mood disorders. 
Since Riluzole is a glutamate-modulating agent for neurodegenerative diseases, Zarate et. al. 
postulated it may reduce excess CNS glutamate in such neuropsychiatric diseases. The study 
took men and women, inpatient and outpatient, ages 18 to 70 years old diagnosed with recurrent 
major depressive disorder with no psychotic features and treated them, after a 1-week drug free 
period, with Riluzole for six weeks. The starting dose was 50 mg but the dose was increased 
after two weeks by 50 mg a week until reaching the patient’s point of toleration or the maximum 
tested dosage of 200 mg/day. No individual or group therapy was allowed during the time of the 
trial and the participants were evaluated on a weekly basis using the Montgomery-Asberg 
Depression Rating Scale. Some adverse effects reported included headache (58%), 
gastrointestinal distress (nausea/vomiting) (43%), decreased salivation (47%), constipation 
(32%), and tension/inner unrest (26%) (Zarate et. al., 2004). Only one subject had to be dropped 
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because of their liver function rising 3 times beyond the normal limit but, this ceased after the 
discontinuation of Riluzole. Finally, results of this study showed remission rates comparable 
with those of other antidepressant showing that Riluzole may also demonstrate neurotrophic 
effects “by stimulating the synthesis of brain -derived neurotrophic factor (Zarate et. al., 2004, 
p.173).” This information is significant because conventional antidepressants have be known to 
“increase the expression of brain-derived neurotrophic factor (Zarate et. al., 2004, p. 173)” 
producing anti-depressant effects in preclinical behavioral models. However, authors such as 
Zarate et. al (2004), note that these findings should be cautiously interpreted due to limited 
sample sizes or other mechanisms of action that might vary among individuals in treating mood 
disorders (Zarate et. al., 2004). 
By using the information found on Riluzole through previous studies coupled with 
literature on future uses of Riluzole for mental health, there was inspiration to conduct further 
research and experimentation with Riluzole for this thesis. Since the drug is fairly new, this will 
help to further speculate on the future potential of this drug. The goal of studying Riluzole 
further is to uncover and prevent side effects and hopefully hypothesize alternate medical uses. 
Uncovering information regarding other studies involving Riluzole allowed me to fine tune my 
own experiment by observing methods and equipment previously used and either adopting those 
methods or steering away from those methods if they were proven inaccurate or inefficient. Data 
found regarding the average dosage, half life, and dosing time frame from previous researchers 
allowed for formulation of an experimental protocol- a structured plan in place that can be 
followed to produce conclusive results. This led to the interest in our own thesis experiment of 
determining what kind of effects Riluzole had on spatial memory, coordination, and fatigue in 
male and female mice at varying dosages. Memory in particular was a topic of interest because 
there have been so many studies as of late into Riluzole being used across other diseases such as 
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Alzheimer’s because of the success Riluzole had in reducing amyloid beta plaque buildup which 
is a defining factor in the development of Alzheimer’s.   
Alzheimer’s Disease is the most common type of neurodegenerative disorder shown 
through memory loss and cognitive decline mainly due to the build up of amyloid plaques. A 
mouse modeled experiment was set up by Okamoto et. al. using 5XFAD transgenic mice that 
exhibit early Aß (amyloid ß peptide) accumulation as well as amyloid ß precursor protein (APP) 
and presenilin mutations (Okamoto et. al., 2018) to see if Riluzole would have any effect on 
reducing these factors. These mice were treated with Riluzole from 1 to 6 months of age. 
Riluzole was shown to have a significant effect on enhancing cognition, through strengthening 
neural communication as see in later observations of the mice hippocampi, and reducing several 
oligomer levels plus the overall Aß plaque load- which is the most prominent contributor to AD. 
Okamoto et. al.’s (2004) research showed significant effects shown via Riluzole in the 
hippocampus causing reversal in several negative gene expressions of the mice, including in 
NMDA receptor subunits for gene expression essential in learning and memory. It should be 
noted, only male mice were used in the experimentation and they were given 13 mg/kg of a 
Riluzole solution per day because this dose had previous reported success in improving cognition 
and reducing tau pathology in AD mice. The Riluzole given to the 5XFAD was a solution 
because it was dissolved in room temperature tap water for about six hours shielded from light 
exposure by foil coverage. This solution was then diluted into the mice drinking water by 
determination of the animal’s weight and water consumption over the previous 24 hours. After 
they were acclimated to the same room as the test a day prior, the mice were initially run through 
a Y-maze to test their hippocampal-dependent spatial memory retention (Okamoto et. al., 2018). 
Riluzole showed a significant effect in reversing aspects related to causing AD presumably 
because of Riluzole’s ability to regulate glutamatergic synapses. This regulation allowed for the 
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reduction of Aß levels and gene expression implicated in microglial activation and synaptic 
transmissions (Okamoto et. al., 2018).  
Additionally, Rinwa et. al. (2012) designed a study to investigate the potential of Riluzole 
with incidences of memory deficits associated with dementia in mice (12 weeks in age). It should 
be noted, the author included information on how estrogen is known to improve memory so they 
equally distributed male and female mice in all the groups (10 groups of 8 mice each). The mice 
were on a pellet chow and water diet and were exposed to natural light and dark cycles. The mice 
were acclimated to the laboratory conditions five days prior to the behavioral study. Riluzole was 
administered in doses of 5 and 10mg/kg intraperitoneally. A Morris water-maze (MWM) divided 
into four quadrants was used to test the learning and memory of the animals. Each animal was 
subjected to four consecutive training trials on each day with an inter-trial gap of 5 minutes. 
Each mouse was placed in the water between quadrants and the drop location changed for each 
trial. The mouse was given 120 seconds to locate the submerged platform and was allowed to 
stay on the platform, when found, for 20 seconds. If the mouse could not find the platform in the 
time frame, it was manually guided to it. Their mean escape latency time (ELT) was recorded on 
day 4 to index their learning. On day 5, the platform was removed and the mice were allowed to 
roam freely for 120 seconds (Rinwa et. al., 2012). The mean time spent in all four quadrants was 
noted as well as the time spent in the target quadrant where the platform was normally placed. 
Rinwa et. al. (2012) found Riluzole significantly reversed STZ and NaNO2-induced memory 
deficits as shown through the increase in MWM performances by the mice. Riluzole was also 
shown to produce a significant decrease in brain neurotransmitters (AChE) activity and oxidative 
stress (Rinwa et. al., 2012). This literature is very important because it gives an account into 
memory issues in association with Riluzole, which is part of our own experimentation. Reading 
this article makes the experimentation portion all the more interesting because we are 
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investigating if Riluzole causes memory issues while this article claims that Riluzole helped 
repair memory deficits. It will be interesting to see if we contradict this study or correlate it in 
relation to our own hypotheses. It has given an interesting perspective to the workings of 
Riluzole but it has not biased our current experiment.  
Finally, research interpreted by Sugiyama et. al., (2017) found that a systemic 
administration of Riluzole showed to enhance recognition memory in rats run through the NOR 
test- although the mechanisms behind the effect remain unclear. Sugiyama et. al., (2017) wanted 
to test a different administration of Riluzole by intra-BLA administration. Male Wistar rats, that 
were 12 weeks old at the beginning of the experiment, were used. The drugs were dissolved in 
saline and infused through 30-gauge injection cannulas. The drug was delivered over a 1 minute 
period and the rats were kept in their cages for 5 minutes before going through behavioral 
testing. Both the novel object recognition (NOR) and elevated plus-maze test were used 
(Sugiyama et. al., 2017). Adult male Wistar rats “were bilaterally cannulated in the basolateral 
amygdala (BLA) (Sugiyama et. al., 2017, p. 98).” because the BLA plays a role in both 
recognition memory and anxiety regulation. Administration of Riluzole did enhance the 
recognition memory in rats and showed anxiolytic-like effects in rats as learned by Sugiyama et. 
al., (2017) . They believed this was because, since Riluzole “has been shown to inhibit voltage-
gated sodium channels, inhibit activation of voltage-gated Ca2+ channels, inhibit GABA uptake, 
potentiate glutamate uptake, and block post-synaptic glutamate receptors without direct receptor 
interaction (Sugiyama et. al., 2017, p.101),” that it was able to decrease the excitability in the 
BLA causing reduced anxiety. It is suggested that recognition memory is strongly affected by the 
rodent’s anxiety. Riluzole also caused changes in the trafficking of AMPA receptors (modulator 
CX691 known to increase synaptic responses and enhance persistent strengthening of synapses- 
potentiation) so it is also possible that this modulation enhanced the rat’s recognition memory. 
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Sugiyama et. al. note further studies are needed to fully determine the underlying memory 
enhancing effects of Riluzole and that it is not an indirect effect from the type (intra-BLA) of 
administration.  
Overall, there is limited information on the effect Riluzole may have and whether or not 
it can be used for other medical purposes. It is also important to further study the extent of side 
effects and symptoms this drug can have when administered chronically. Thus, the purpose of 
this honors thesis was to investigate whether Riluzole causes any effect on fatigue, measured by 
subtasks of coordination, endurance, and stereotypic movements, as well as evaluating the 
effects of memory including recollection, spatial memory, and directional memory. In this mouse 
study, recollection will be defined as the ability of the mouse to find its way back to a food 
source by remembering specifically where it was placed after being shown. Spatial memory is 
referring to memory information about the surrounding environment and spatial orientation. 
Reference to directional memory is in terms of not necessarily recalling previously learned 
information, but being able to determine how to orient oneself to a location and use logic to 
determine the correct pathway from point A to point B.  In this study it was also important to 
perform a dose-response evaluation of Riluzole both acutely and chronically since research 
demonstrated there is not one definitive dosage that is best for this drug, rather it may depend on 
the individual.  
Based on previous work and current research, this thesis hypothesizes Riluzole will cause 
a significant increase in motor performance (endurance and/or coordination) in mice as 
compared to controls. It is also predicted from current literature that the highest dose of Riluzole 
will cause more fatigue in animals as compared to controls.  More specifically, it is predicted that 
males will produce more errors in the maze while females will exhibit more stereotypy-like 
behavior because of female’s tendency to be calmer and more calculating in their movements. 
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Finally, dose-dependent differences between males and females on spatial and temporal memory 
are predicted to be present, but not significant. 
Method 
Subjects 
 Thirty-four adult male CD-1 mice (weighing 38-54 g) were purchased from Charles 
River Laboratories, (Portage, MI) and maintained throughout the study at the LIU-Post Animal 
Vivarium.  Mice were housed in groups of 6 to 10 in Plexiglas cages and maintained on a 12-h 
light / 12-h dark cycle, with lights on at 8am.  Food and water was available ad libitum.  Mice 
were randomly divided into 4 groups depicted by control (n=6), low (n=9), moderate (n=10), or 
high (n=9) dosage of Riluzole for the pilot experiment. Male (n=7) and female (n=6) mice were 
separated and randomly grouped as control, low (n=3 male & 3 female), moderate (n=3 male & 
3 female), or high (n=3 male & 3 female) dose of Riluzole for further experiments on 
coordination, recollection, stereotypy like movements, and directional memory. Each subject was 
officially tested only once in each apparatus, in whichever dose they were assigned, and studies 
were carried out in accordance with The National Institutes of Health Guidelines and regulations 
specified by the LIU-Post Animal Care & Use Committee.   
Drug 
 Riluzole (Rilutek) was purchased from Sigma Aldrich through funding of the LIU-Post 
Monetary Grant.. Riluzole was weighed and diluted with .09% saline. Mice were divided into 4 
groups, namely a control group that received saline (n=6); a group that received a low dose of 
Riluzole (n=9); a moderate dose of Riluzole (n=10); and a high dose of Riluzole (n=9) all via 
0.2cc injection volume.   The 3 doses were as follows: 1.380mg (low dose), 8.591mg (moderate 
dose), 17.215mg (high dose) of Riluzole for a 1:5:10 concentration ratio. The animals were 
always tested at the drug’s peak time of effect (i.e., 90 minutes after injection). 
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 Apparatus 
 The Coulbourn Tru-Scan Activity Box consists of two clear Plexiglas chambers, 
measuring 9 inches x 9 inches, each surrounded by photobeam sensor rings, sized to the 
dimensions of the small and large arena, which sense in two dimensions. Photobeam sensors 
detect the floor plane (FP) sensing, nose poke (NP), and rearing or vertical plane (VP). The 
Plexiglas chambers are equipped with a nose poke measurement food pellet tray underneath the 
floor that can sense pellet removal and repetitive entry in the poke holes to provide a full analysis 
of the sequence or repetitive entries into the holes where the food pellet can be hidden. The nose 
poke floor consists of a grid of 4x4 holes that lies above the food tray. It is elevated to just the 
right height for the beams to pass between the tray and the floor so that an animal’s nose is 
detected when it crosses the barrier of one level into the other. This is an optimal tool for 
analyzing spatial learning and memory testing. Automated protocols using Tru scan software 
were designed prior to the experiment to run automatically once the animal is placed into the 
chamber.  Behavioral activity data is then recorded on all chosen data acquisition variables 
(Coulbourn Instruments, 2000). This apparatus was specifically used to assess spatial memory 
following Riluzole exposure in both male and female mice.  
The second apparatus used in the study was a wooden maze.  This device was used for 
the assessment of temporal and directional (spatial) memory. The box consists of a 2 foot by 2 ft 
square enclosure with a clear plexiglass top which allowed the researcher to non-invasively 
observe the animal’s sequence of actions within the maze. The goal of this device was slightly 
different than the Coulbourne Tru Scan Activity Chamber.  The animal needed to complete a 
series of sequential actions in the correct manner in order to make it from the beginning of the 
maze to the end of the maze.  After placing each mouse at the “start point,” elapsed time was 
recorded until the mouse reached the “end zone, where a fruity pellet was placed to entice them.  
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While navigating the wooden-walled maze, one at a time each mouse was placed in the maze at 
the peak time of drug effect and data was collected on each mouse.  
The third apparatus used in the study was a large rotating machine called a Rotorod. A 
Rotorod (series 8 model,) from the IITC-755 Life Sciences Company (Victory Blvd, Woodland 
Hills, CA 91367), was used to test ataxia (coordination) and more specifically the drug’s effect 
on coordination and fatigue. The Rotorod apparatus has five, separate enclosed, raised lanes with 
rotating rods of 1.25” diameter in each lane.  This rotating rod is suspended above a platform.  
Each lane is self-contained so the mice cannot see each other however it is open to viewing by 
the investigator through the front Plexiglas panels. Once the mice are placed atop of the 
stationary rod, the rotating drum starts slowly and causes the rod to rotate whereby the animal 
needs to walk or run to keep its balance. This machine can be automated to record balance, 
endurance, and overall ataxia (coordination).  The pace of the rotating rods can be set at will and 
were initially formatted during baseline studies.  The speed of the rotating rods were designed in 
this study to force a moderate walking pace in the mice, unless the animal became ataxic (i.e., 
uncoordinated) and fell off the rotating rod. Typically, animals stay on the machine for longer 
periods of time as they build up endurance.  In this study the investigators had a cutoff time of 
two minutes in order to not fatigue any animal. Underneath the rotating drum in each lane is an 
lower platform that is balanced like a “see-saw” above two metal sensors at the front and rear 
end of the lane that detect when the animal falls off of the rotating rod to the platform. When the 
mouse falls from the rotating device (18.5cm from drum to platform), it’s weight is distributed to 
either the front or the rear of the platform, causing it to lean in that direction and initiate the 
trigger below. Initiating the trigger signifies that the mouse has fallen and the testing parameters 
cease in their recording. The Rotorod machine records rpm’s (revolutions per minute), time spent 
(in seconds), and the distance traveled (in meters). These results were displayed continuously 
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through the study and the length of the overall testing. When all mice have fallen from drums in 
the occupied lanes, the Rotorod displays the statistics for each lane independently. The latency 
(in seconds) for each mouse is displayed and was specifically used when comparing the 4 groups 
of mice. In order to minimize any effects due to learning, each mouse was baselined three to four 
times prior to the study. This allowed for an acclimation to the rotating wheel, making sure the 
results were not debased by being un-adapted to the machine as opposed to any actual effect 
from the drug. This apparatus was utilized again following post-Riluzole treatment.  
Finally, a scale (recording to the hundredth of a mg) was used to document the weight of 
each mouse prior to testing to identify the correct average dosage of Riluzole to administer per 
level (low, moderate, or high).  And various colored sharpies were used to mark the mice in 
unique patterns, to distinguish them from one another when testing and recording individual 
results. 
Procedure 
 The study was conducted in a Life Sciences laboratory on the LIU-Post campus. Prior to 
testing, baseline measures were taken for the male and female mice with the activity box 
apparatus, testing for repetitive movements, and the wooden maze apparatus, testing for 
problems with directional memory. Two groups of 4 female and 4 male mice were also assessed 
in the activity box for spatial memory. Each mouse in the female group was randomly assigned 
to receive the control (n=1), low dose (n=1), moderate dose (n=1), or high dose (n=1) of 
Riluzole. The same assignment was given to each mouse in the male group. The female group 
was randomly run first followed by the male group. The mice were injected with 0.2cc’s of the 
control (saline), low (1mg/kg), moderate (5mg/kg), or high (10mg/kg) Riluzole dosage. Testing 
in the activity box was conducted, independently, once every 30 minutes following injections, 7 
times total. A flavor pellet was placed in 1 of 9 peg holes in the activity box. Every time the 
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mouse looked in the wrong location for the flavor pellet, an error was recorded. The total number 
of errors during each of the 7 testing periods were recorded for each mouse.  
One week later, 8 male and 8 female mice were acclimated to the wooden maze prior to 
testing with Riluzole in their system. The subjects were first evaluated in the wooden maze with 
no injection and several different flavored fruity food pebbles were put at the correct exit of the 
maze to determine which flavor was more enticing to the mice. Presumably, by using a pellet 
more favorable to the subjects at the end of the maze, it would be incentive to find the exit. The 
mice, male and female, on average preferred the orange food pebble which was then used in the 
testing procedure. The mice were run through the wooden maze three times each to learn the 
pathways and directions of the maze. Immediately after acclimation, the male mice and female 
mice were injected with a high dose of Riluzole (10mg) at an injection volume of 0.2cc’s. Thirty 
minutes after the time of injection, the mice were evaluated in the wooden maze to determine if 
they could find the correct passage to get out. Each mouse was run individually, the male group 
first (by random decision) followed by the female group, and the number of errors they made in 
the maze were recorded. An error was denoted by reaching an end of a pathway that was blocked 
and not a viable path to the exit, resulting in the need to turn around and choose a different path. 
A stopwatch was used to measure the elapsed time and errors were counted through tally marks 
upon observation by the researcher. Each mouse was tested in the wooden maze one time after 
injection in determination of their directional memory.   
After two weeks, six male mice and six female mice were injected with a high dosage 
(10mg) of Riluzole at an injection volume of 0.2cc’s. Thirty minutes after injection, the mice 
were evaluated, individually, being placed in the activity box. Each mouse was observed for two 
minutes each to assess the amount of time spent, in seconds, spinning or rotating on the same 
plane resulting in the presence or absence of stereotypy. The amount of time elapsed and the 
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repetition of movement were recorded through the Tru Scan 2.0 Software. The female mice were 
run first, by random selection, followed immediately by the male mice. Individual times were 
recorded in the data under the respective group of each mouse, male or female.  
A between subjects design was used for the first pilot study on the Rotorod testing the 
effects of Riluzole on coordination and endurance in a broader attempt to see if Riluzole caused 
any fatigue. The scores between the 1mg dosage, 5mg dosage, and 10mg dosage were compared 
to the control and all mice were tested at only one of those dosages. However, all mice were 
tested in both subtasks of coordination and endurance. This pilot study was conducted separately 
and approximately 4 months prior to the repeated measures Rotorod design spanning over three 
weeks, with a different population of mice, to the other testing in the wooden maze, activity box, 
and further Rotorod analysis.  
 Four cages of mice were randomly assigned to either control (no Riluzole), low dose 
(1mg/kg) , medium dose (5kg/mg), or high dose (10mg/kg) for the experiment. A total of 34 
mice were used: n6= control, n9= low dosage, n10= medium dosage, n9= high dosage. Initially, 
each mouse was weighed on the scale to find the average weight per cage. The average weight 
per cage was used to calculate how much Riluzole should be weighed out and diluted with saline 
to comply with the 1:5:10mg/kg dosage ratio. Each mouse in the cages were given a distinct 
mark with a red, green, or black sharpie to identify them from one another during testing. After 
being marked, the cages of mice were run on the rotorod without any Riluzole in their system to 
record their baseline scores. Each cage was run separately with five mice per session (1 mouse 
per lane). Three baseline trials per cage were performed to ensure the mice were acclimated to 
the Rotorod to account for measurement error that could happen from unfamiliarity with the 
machine. There were five min rest periods between each trial. Each mouse was moved one lane 
to the right (from their original placement) each new trial to avoid any practice effects. Their 
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baseline scores for time and distance were recorded and used as the control to be compared to 
their treatment scores with Riluzole.  
 The mice were given three i.p. injections of Riluzole (or saline for control) with 3-4 days 
between injections. All injections were administered within 3-5 minutes between cages so they 
had no significant difference when reaching the peak effectiveness of their dose before testing. 
Riluzole’s half-life 12 hours, reaching a steady state after 5 days, and takes 90 minutes to reach 
its peak effectiveness upon injection. The mice were recolored between injection periods as their 
identifying marks began fading. At the peak time after the third injection, the mice were retested 
on the rotorod. Each cage was run for four trials with a five min break between trials. The scores 
for time (sec) and distance (m) were recorded for the performance of each mouse when treated 
with Riluzole. The control group was also put through the additional four trials after baseline 
testing however their scores reflect no treatment with Riluzole.  
 One week after the assessment of stereotypy-like sensations and movement, 12 
mice total, 6 male and 6 female, were randomly divided into four groups: n3= control, n3= low 
dose, n3= moderate dose, or n3= high dose subjects. Control subjects (n=3) were injected with 
0.2cc’s of saline solution. A 0.2cc injection of Riluzole drug solution was administered to the 
low dose (1mg/kg), moderate dose (5mg/kg), and high dosage (10mg/kg) groups once daily for a 
period of 7 days. On the 7th day, each group was tested on the Rotorod at 8 different time 
intervals following the administered injection. Testing was conducted 15min, 30min, 60min, 
90min, 120min, 180min, 210min, and 240min after injection of Riluzole or saline (control). At 
each time interval, the elapsed time (seconds) spent running on the Rotorod was recorded for 
each mouse individually under their respective group. All mice were acclimated to Rotorod with 
3 unrecorded trials each prior to the first week of treatments but tested only once on the Rotorod 
following the injection period. Injections were administered daily at the same dosages for the 
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same subject groups after the 7th day to then reassess after two full weeks of treatment. On the 
14th day, after injections, each mouse was run once on the Rotorod at 15, 30, 60, 90, 120, 180, 
210, and 240 minutes intervals. The elapsed times, seconds, spent running on the Rotorod were 
recorded for each individual. Injections continued the next day to start the third week of once 
daily treatments, at the same dosage levels per group, before reassessment. On the 21st day of 
injections, each mouse was run on the Rotorod once more at 15, 30, 60, 90, 120, 180, 210, and 
240 minutes after injection. The elapsed time, seconds, spent on the apparatus were individually 
recorded for the last time.  
Data Analysis 
The number of spatial memory errors in the activity box for female mice and male mice 
were recorded into separate spreadsheets and compiled into two bar graphs, male and female, 
using GraphPad Prism. Statistical significance (p<.05) was assessed for spatial memory in 
GraphPad Prism using a two-tailed paired t-test comparing two means at a time. The means of 
the low, moderate, and high dose were separately compared to the control group. An RM 
(repeated measure) one-way Analysis of Variance (ANOVA) with Geisser-Greenhouse 
correction was used to compare the means of all four groups together to assess for any statistical 
significance amongst any of the dosage groups.  
 A two-tailed unpaired t-test was analyzed through GraphPad Prism software for each 
dosage individually compared to the control to determine if there is any statistical significance 
(p<.05) within males and females regarding their duration stereotypy or spinning-like sensations 
in the activity box. Additionally, a two-way ANOVA was used to determine any statistical 
significance between the two sexes. The same statistical analyses were used to identify gender 
differences in the number of errors within the wooden maze. Descriptive statistics determined 
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through GraphPad Prism including mean, range , and standard deviation of scores for males and 
females were detailed for activity box and wooden maze tests.  
The data from the baseline trials and the Riluzole trials of the pilot study were compiled 
into GraphPad Prism to analyze the results. The analysis was separated into coordination, by 
using the recorded figures from the time in seconds the mice spent on the Rotorod, and 
endurance, by using the numbers recorded from the distance in meters the mice traveled during 
testing. An unpaired, two-tailed t-test analysis was conducted to compare the means of two 
dosage groups at a time. This unpaired t-test was used to compare the low, moderate, and high 
dosages individually to the control group in both separate analyses for coordination and 
endurance. A One-way ANOVA (analysis of variance) was done to compare the means of three 
or more groups together. This was also done for both separate analyses of coordination and 
endurance to compare all four dosage groups at the same time. Interactions and main effects with 
a p value <.05 were determined to be significant results.  
Statistical significance (p<.05) of Riluzole time action curve vs. dosage for weeks 1, 2, 
and 3 of treatment were assessed by GraphPad Prism statistical analysis software using a 
correlation since this is continuous data looking for the relation of time spent on the Rotorod to 
each dosage level. The confidence interval of r and Pearson correlation coefficients were 
computed for every pair of data sets. Two-tailed P values were evaluated to a 95% confidence 
interval. Unpaired t-tests were further used to evaluate if there were any differences between the 
different dosage groups individually compared to the control group.  
Results 
 Riluzole at the moderate (5mg/kg) dosage (M=2.14, SEM= 0.633) significantly affected 
the number of errors in spatial memory for female mice when in the activity box, t(6)= 2.521, 
p= .0453, as well as at the high (10mg/kg) dosage (M=2.00, SEM= 0.617), t(6)= 4.044, p= .0068 
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(see Figure 3a). Riluzole at the low (1mg/kg) dosage (M=3.93, SEM= 0.639) did not significantly 
affect the spatial memory of the female mice in relation to the female control subjects t(11)= 
0.3704, p=.7181 (see Figure 3a). For male mice, Riluzole at the low dose (M=5.29, SEM= 
0.969)- t(12)= 1.139, p= .2769, moderate dose (M= 5.29, SEM= 1.23)- t(12)= 0.9097, p=.3809, 
nor high dose (M=3.00, SEM= 1.05)- t(12)= 1.060, p=.3102, produced any significant differences 
in the spatial memory in the activity box compared to the male control subjects without Riluzole 
(see Figure 3b).  There was a statistically significant difference in sex, males (n=7) and females 
(n= 6), and the number of errors made in the activity box, F(1,44)= 10.20, p = .0026.  
 Riluzole at a high dosage (10mg/kg) produced significantly more directional memory 
errors amongst the male mice (n=8, M=10.13, SEM= 2.295) than the female mice (n=8, 
M=3.375, SEM= 0.4978) in the wooden maze, t(14)= 2.875, p=.0122 (see Figure 4).  
There was no statistically significant difference between male mice (n=6, M=24.33, 
SEM= 5.542) and female mice (n=6, M=12.17, SEM= 2.786) with a high dose of Riluzole 
(10mg/kg) in the time they spent (sec) demonstrating any stereotypy or spinning-like 
movements, t(10)= 1.962, p= .0782 (see Figure 5).  
Scores for time were analyzed under coordination and scores for distance were analyzed 
under endurance. Looking at Figure 6, our initial hypothesis was partially supported in the 
assumption that Riluzole would cause fatigue. However, our results were only significant for 
coordination at a 1mg dosage and endurance at a 5mg dosage between figures 6a and 6b, not all 
groups. Plus, the endurance levels at a 10mg/kg (high) dosage showed scores either almost 
equivalent to the control while coordination scores at a high dosage were higher than the control.  
 The data for coordination in Figure 6a showed the control group (M= 9.7, SEM= 0.46) 
spent significantly more time on the Rotorod compared to the 1mg treatment group (M= 7.9, 
SEM= 0.66), t(9)= 2.063, p= 0.0411. While there were no significant effects between the control 
BEHAVIORAL EFFECTS OF RILUZOLE 
 
41 
group (M= 9.7, SEM= 0.46) and 5mg treatment group (M= 8.5, SEM= 0.46) in their time on the  
Rotorod, t(10)= 1.532, p= 0.1279, Figure 6a showed the 5mg treatment group spent less time on 
the Rotorod. The effects between the control group (M= 9.7, SEM= 0.46) and the 10mg treatment 
group (M= 10.6, SEM= 0.62) were also insignificant, t(9)= 1.024, p= 0.3079, Figure 6a 
suggested the mice in the 10mg treatment group ran longer on the Rotorod.  
 The 5mg treatment group for endurance in Figure 6b (M= 0.086, SEM= 0.008) ran 
significantly less distance than the control group (M= 0.119, SEM= 0.009), t(140)= 2.104, p= 
0.0372. While there were no significant effects between the control group  and 1mg treatment 
group (M= 0.090, SEM= 0.011), Figure 6b showed the 1mg treatment group did not run as far on 
the Rotorod. The effects between the control group and the 10mg treatment group (M= 0.113, 
SEM= 0.009) were also insignificant, t(136)= 0.3444, p= 0.7311, Figure 6b suggested the two 
groups ran about the same amount on the Rotorod - the 10mg treatment group possibly ran 
slightly less through initial observance of the charted data.  
 It should also be noted, from personal observation, that the mice were visibly calmer in 
their demeanor by their third injection. They did not struggle as much during the final injection 
and they were not as hyperactive in their cages afterwards in comparison to first interactions with 
them prior to any Riluzole injections.  
 During the first week of treatment with Riluzole, results of the Pearson correlation 
indicate there was no significant correlation of the dosage at the control, low (r = .3659), 
moderate (r = .3553), or high (r = .5664) levels to the elapsed time (sec) spent running on the 
Rotorod. There was also no statistical significance between any of the dosage groups compared 
to the control group (see Figure 7a) through individual unpaired t-testing. The second week of 
treatment showed no significant correlation between the control, low (r = .8512), moderate (r 
= .7688), or high (r = .7811) dosage groups to in time (sec) spent running on the Rotorod. 
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However, there was a statistically significant difference in the unpaired t-tests in the time spent 
on the Rotorod between the high dosage (n=3, M= 45.21, SEM= 4.185) and the control group 
(n=3, M= 80.83, SEM= 3.612), t(6)= 6.444, p<.001 (see Figure 7b).  The third week of treatment 
showed a moderately positive correlation between the high dosage of Riluzole (n=3, M= 41.04, 
SEM= 4.621) and the amount of time (sec) spent running on the Rotorod, r(4)= .8362, p= .0097, 
with an R2 of .6992. There is also a statistically significant difference between the high dosage 
group and the control dosage group in the time both spent running on the Rotorod, t(6)= 5.932, 
p<.001. 
Discussion 
 Based on our results, the sample of female mice showed significantly less errors in the 
activity box amongst the moderate and high dosage groups in comparison to the control group. 
This can be interpreted that the ability for the female mice to recollect what peg hole, out of nine, 
was actually improved the higher the dosage of Riluzole they were given (see Figure 3a). This 
goes completely against the original hypothesis predicting that the higher the dosage of Riluzole, 
the harder it would be for the mice to recollect where the food was placed. This would lead us to 
believe that Riluzole at an average dose or higher could have benefits for certain aspects of 
memory and possibly preserve this functioning in the face of a disease of deterioration, such as 
ALS. However, these results are only reflective of the female mice whereas the same testing 
conducted on the population of male mice showed there were no significant differences in the 
number of errors made depending on the dosage of Riluzole. This would support the null 
hypothesis regarding differences within each sex. At the same time it defies the null hypothesis 
of no differences between the sexes because there is a difference in the number of errors made in 
the activity box when comparing the male to female mice. In general, by looking at Figure 3a 
and b, we can see that male mice made slightly more errors overall trying to recollect what peg 
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hole the food pellet was hidden in. This is especially apparent at the moderate dosage level 
which seems to show many more errors made by the male mice than female mice. Additionally, 
while there appears to be a large reduction in the number of errors between the low and moderate 
dose of the female mice, the number of errors at both these doses stayed nearly the same for the 
male mice showing no distinct difference until observing the reduced number of errors at the 
high dosage. Thus, the null hypothesis for no difference between sexes is invalid because there is 
an observable difference between the errors made by females compared to males, although we 
cannot speak to the level of significance. This provides an interesting perspective because now 
we must ask why it was so much more effective in improving recollection for females in general 
and as opposed to males. Is this difference because of a natural difference in female versus male 
recollective memory or is this solely due to the drug? Maybe, female memory is already 
naturally more adept to recollective memory function and Riluzole is a further enhancement. In 
addition, then would Riluzole be a more beneficial treatment for one sex, females per say, rather 
than the other? These are all questions that would require further research and experimentation. 
However, because we ran the female mice before the male mice, we do not know if the results of 
the male mice could have been influenced by a potential scent trail left by the female mice. This 
could be a point of speculation to correct for in future research. 
 Continuing to explore differences of sex to the effects of Riluzole, the results establish 
males made more errors in the wooden maze compared to females at the highest dosage. This 
demonstrated that males had more problems utilizing their directional memory trying to find 
their way to the correct exit in the maze while females directional memory was much more 
intact. Riluzole at a high dosage level had very little impact on the female subjects. In fact, just 
through observation of Figure 4, it seems that the high dosage of Riluzole did not alter their 
directional memory from its original capacity represented by the baseline marker. Males had a 
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much harder time figuring out the way to the exit of the maze when on Riluzole. This proves our 
null hypothesis to be untrue because there was a significant difference in the number of errors 
made between sexes. Although, in this testing we happened to run all the male mice before the 
female mice, so we must question again if there was some sort of scent trail the males may have 
left that the females noticed during their testing and possibly altering their results. This could be 
an additional variable that we were unaware of at the time of our study but could be employed in 
future research for clearer results and interpretations. However, overall, this information does 
prove in favor of our actual hypothesis stating males would make more errors during this portion 
of testing based on notions formed personally that females have better overall memory capacity.  
 While the next phase of testing did not involve memory, our results continued to assess 
the differences between genders but showed there was no indisputable difference in the amount 
of time a mouse exhibited repetitive movements or spinning-like sensation at a high dose of 
Riluzole. Looking at Figure 5 appears as though males did spend more time than females 
repeating movements in the activity box, but we cannot say with confidence that the high dose of 
Riluzole caused these behaviors. The null hypothesis in this case is supported since we can 
neither say with statistical certainty that there was a difference between male and female mice 
nor was it Riluzole that caused these actions. Maybe if this test was done with a larger sample 
size for both sexes there would be more evidence to form a better interpretation of whether 
Riluzole is at all a cause to these sensations, whether it has more of an effect on one sex 
compared to the other, and if there is a general difference between males and females to 
demonstrate repetitive movements. This would be interesting to further investigate due to the 
results of the study in the wooden maze where the male mice showed less success using 
directional memory. If they were unable to locate the exit of the maze, then this would mean they 
would have to turn, or spin, around to maneuver to a different path and, depending on the 
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number of errors, they may have repeated their mistakes several times. This causes a question of 
whether the lack of directional memory in the male mice is at all related to them seemingly 
having more repetitive movements, whether or not Riluzole was a factor. While observing the 
mice during testing, the male mice seemed almost unsure in where to go but have more need for 
quick, constant movements to find the exit in the maze. On the other hand, the female mice 
seemed possibly calmer, maybe more precise, in their movements while discovering their way 
out.  
Based on our research, we are able to conclude that the mice had greater endurance and 
more coordination with the 10mg/kg dose of Riluzole. The mice consistently maintained better 
coordination and endurance levels at the 10mg/kg dosage. We rejected the null hypothesis 
because there was a significant difference in some scores. This defied the original hypothesis 
initially thinking that the levels of fatigue would be greater at a higher dosage of Riluzole. The 
fact that the figures show the scores at the 10mg/kg dosage are about the same level or higher 
than the control groups suggests that this higher dosage produces very little fatigue in the mice, if 
any at all. It also rejected our more general hypothesis that any dosage of Riluzole will cause 
fatigue because, while Figures 6a and 6b show the decrease in coordination and endurance 
correlated with fatigue in the 1 and 5mg dosages, it does not have this effect on the 10mg dosage. 
We concluded that the dosage level of the Riluzole being administered determines the level of 
fatigue experienced, if at all. However, we can interpret, based on our results and tables, that 
Riluzole can cause fatigue in those who use it.  
 Interestingly, we found that the mice were noticeably less coordinated with a 1mg dose 
when compared to their pretreatment scores, as shown in Figure 6. This suggests that the mice 
were having difficulty staying on the Rotorod once they were administered the Riluzole even at a 
lower than average dose. This could be due to being too tired to orchestrate moving one foot in 
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front of the other to keep up with the spinning column and be an effect in their brain on their 
muscle control systems. That is something that would have to correlated with further research 
and more in-depth tests and brain imaging to confirm that the problem lies at a  neuronal level 
and that it is because of Riluzole in particular. Also, based on our initial data, with a larger 
sample size, there may have been a significant effect in the decrease of endurance levels at the 
1mg dose. The level was not significant at p= 0.0856, but this is rather close to our threshold of 
p<0.05. The mice also showed significantly less endurance at the 5mg dose. Overall, both the 
low dose (1mg) and the moderate dose (5mg) showed higher levels of fatigue in the mice than 
the high dosage. This is an odd finding that requires further speculation on if the high dosage had 
lost it’s effect and that is why the results were so different, or if a higher dosage of Riluzole is 
actually more beneficial, or effective, than other dosage levels at the current average or below.  
 Based on the findings in this study, it implied that there should be further research of the 
drug Riluzole. Our research has lead us to further question whether the current recommended 
dosage of Riluzole for patients is the most effective. The moderate 5mg/kg dose used in this 
experiment comes from the average recommended dose for Riluzole typically prescribed to 
patients. However, looking at the data as well as Figures 6a and 6b, we saw that the mice had 
better coordination and more endurance on the 10mg dose than the 5mg dose. This means that 
the higher than average dose at 10mg had less of an effect of fatigue than the current 
recommendation of 5mg/kg that is prescribed. On the other hand, these results could also be due 
to our mice being regular, healthy mice unaffected by a disease such as ALS. We have to further 
consider if the effects would be different on a healthy mouse compared to a mouse in a 
degenerative state. Thus, there should be a second study done to confirm that the higher dosage 
had less of a negative effect. However, doctors and scientists should look into how effective the 
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current recommended doses are for Riluzole to ensure that patients are being given the best 
treatment plan possible.  
 In the final testing on the Rotorod, the fact that there was no significant correlation 
between any of the dosage groups and the time they spent running on the Rotorod after the first 
week of treatment, tells us that Riluzole is not affecting how long the mice are able to run on the 
Rotorod for at this point in time. After only one week of treatment the mice are exhibiting what 
we can assume to be normal levels of coordination as there are no significant differences 
between the low, moderate, or high dosage level and the control group either. We can even see in 
Figure 7a that the scores for each dose over time encompass roughly the same amount of elapsed 
time as well as a similar pattern over the time of injections. This supports our null hypothesis 
because we see no differences in coordination, or time spent on the Rotorod, across any of the 
four subject groups. The higher dosage also has no significant effect, which means at week 1 of 
treatment our hypothesis is initially disproved. Within only one week of being on Riluzole, 
maybe it is not well enough acclimated in the body’s system to produce any positive or negative 
effects on a subject’s coordination. At the second week we see a similar outcome in the results 
where there is no statistically significant correlation between the different dosages of Riluzole 
and the amount of time spent on the Rotorod, meaning that Riluzole is not having an effect on 
coordination in either a positive or negative way. This could be interpreted as a positive attribute 
so far if it is thought about a positive that this drug is not causing any harmful or disabling 
affects from using it. However, since Riluzole’s original purpose was to help combat symptoms 
of ALS, a neurodegenerative disease that is affecting an individual’s coordination by breaking 
down muscles, muscle junctions, and neurons needed for normative movement, it could be a 
severe defect in the purpose of this medication. However, at the end of the second week off 
treatment, while Riluzole was not correlated to the time spent on the Rotorod, there was a 
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statistically significant difference in the amount of time spent on the Rotorod under the highest 
dosage compared to the control group. This showed that the mice were spending less time 
running on the Rotorod at the high dosage than those not given Riluzole. It can be clearly seen in 
Figure 7b where, in general, we can see less of an overlap and more distinction between the 
dosage groups but especially with the high dose which dropped significantly further from the 
control dose showing the mice were having more trouble with their coordination than normal. 
Without a significant correlation we cannot say that their coordination is worse due to the 
Riluzole but clearly the high dose shows a negative effect in relation to what is considered a 
normal level of function (control). Seeing this distribution is a lead as a researcher to think 
maybe the longer the study continues, the more likely we will be able to validate a statistically 
significant correlation because the data seems to be heading in that direction but maybe two 
weeks is still not a viable time period for Riluzole to take a true effect in the system. Since 
Riluzole has a half-life of 12 hours, it raises the question of if clear identifiable effects would 
take place sooner if the drug was administered twice daily as opposed to once daily. Thus, by the 
second week of treatment, the null hypothesis is still accepted as true because there is no 
significant correlation between coordination and any dosage group. However, at week two we 
can say that our hypothesis that a higher dosage of Riluzole would result in less time the mice 
were able to sustain on the Rotorod is correct although we cannot fully support our hypothesis as 
we still cannot link this as correlation to between the drug and coordination- but there is 
something going on. This makes leading into week three of treatment more interesting because 
of the observance of a pattern occurring in the graphs and data sets initially even if it cannot be 
proven yet, so the biggest question is if it was just a fluke or if this will continue over more time 
exposed to the drug. As our results demonstrate, these initial observations should not be 
disregarded because we see during testing at the end of the third week of treatment a moderately 
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positive significant correlation between a high dosage of Riluzole and less time spent running on 
the Rotorod (coordination). This means these two variables tend to increase or decrease together. 
By looking at Figures 7a and c, it can be interpreted that as more time goes on being given the 
high dosage of Riluzole, the worse the subject’s coordination becomes as demonstrated by the 
clear drop in elapsed time spent on the Rotorod from week 1 to week 3.  We also see in Figure 
7c, knowing Riluzole’s peak effectiveness occurs 90 minutes after injection, that as we approach 
the this time of action- from the 60 to 90 and even 120 minute mark- that these produced the 
lowest elapsed times for staying on the Rotorod. The smaller the gap to the drug’s peak 
effectiveness the less coordination the mice had. Overall we can say that these low time scores 
demonstrating difficulty maintain coordination were due to the effects of Riluzole at the high 
dosage level. As shown by our R2 we can report that about 70% of the variance of the elapsed 
time variable and overall demonstration of coordination can be explained by variable of Riluzole 
at a high dosage, and vice versa. After the third week of treatment and testing we again find 
through the unpaired t-test that there is a statistically significant difference between the time the 
control groups spends on the Rotorod compared to the group administered a high dose of 
Riluzole. The control group was able to stay on the Rotorod much longer than those given a high 
dosage which can be easily seen in Figure 7 as there is a large gap between these two groups, and 
from the low and moderate dose although we cannot report those differences with statistical 
confidence. This means that a dose of Riluzole higher than the recognized average may actually 
be more harmful to an individual than helpful which is important to distinguish when prescribing 
to someone in order to help alleviate symptoms and not make them worse. It is also interesting to 
see over the course of the three weeks that the coordination of the mice at the low and moderate 
dosages stayed relatively consistent and close to the normal level of the control group throughout 
testing. These observations cannot be claimed to have a significant meaning or be definitively 
BEHAVIORAL EFFECTS OF RILUZOLE 
 
50 
true, but from pure reflection on the tables it seems they are able to maintain a stable sense of 
coordination in the subjects. This should be further examined to see if there is just no effect 
happening at these dosages of Riluzole and the drug is not working versus if this is a good sign 
Riluzole is working very effectively to keep the subject in a more healthy state.  
Further Implications of Riluzole  
 While we have investigated Riluzole for its effects on subtasks of fatigue and categories 
of spatial memory, many other studies have been in progress over the years to take the positive 
factors of Riluzole that have given some hope to patients with ALS, and see if they can be 
employed across various other diseases both similar and dissimilar to ALS. For example, 
Wadman et. al. (2012)  explored other muscular motorneuron diseases in which Riluzole’s 
usefulness was examined. This article specifically targets Spinal muscular atrophy (SMA) which 
is caused by the degeneration of anterior horn cells of the spinal cord leading to progressive 
muscle weakness. There are three types of SMA (Types I, II, and III)- the research regarded in 
this study focuses on trials regarding SMA type I in children. The information studied focuses on 
children because patients with SMA type I usually die by two years of age and are never able to 
sit up without support. The objective of Wadman et. al. (2012) was to evaluate whether drug 
treatment would be able to slow or stop the progression of SMA type I since, as of publication in 
2012, there are no known drug treatments showing any influence in the disease’s course. 
Wadman et. al. (2012) extracted data from previously conducted trials that were either 
randomized or quasi randomized and with participants who fulfilled clinical criteria as well as 
deletion or mutation of the SMN1 gene; confirmed through a genetic analysis. The primary 
measure from the accumulated research is based on the time from birth until death or full time 
ventilation. The secondary measure is the development of rolling, sitting, or standing within one 
year after the onset of treatment or adverse effects from treatment during the trial period. One 
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analysis in particular identified, conducted prior to 2011, a small randomized controlled study 
comparing treatment with Riluzole to a placebo for 10 children documented with SMA type I. 
Three out of seven children lived to 30, 48, and 64 months when treated with Riluzole while all 
three of the children given the placebo died (Primary measure). None of the children, regardless 
of being given Riluzole or the placebo, developed the ability to roll, sit, stand, nor developed any 
adverse side effects (Secondary measure). However, no statistically significant difference could 
be documented for either measure due to the low quality of the study, for example the children 
from the placebo group having the onset of symptoms at a younger age, and the study being too 
small to prove any significant efficacy (Wadman et. al., 2012). Support from the pharmaceutical 
industry regarding the study was withdrawn due to the lack of power behind the statistical 
significance. Conclusions cannot be drawn considering whether drug treatment could have 
beneficial clinical effects on the disease progression of SMA type I. Overall, the opinions of 
Wadman et. al. (2012) do not advocate children with SMA type I on Riluzole, nor any drug that 
suggested to prolong survival, appear to improve motor function. Future research on possible 
drug treatments, including new trials with Riluzole, need a large randomized placebo-controlled 
study to demonstrate any efficacy (Wadman et. al., 2012). In addition, they suggest future trials 
reporting possible side effects, having the time from beginning treatment to death or full time 
ventilation be the primary measure, daily functioning and quality of life be considered, and a 
new rating scale be developed from the existing standard scale for future trials (Wadman et. al., 
2012). 
Crossing more into the realm of psychiatric illnesses, research by Banasr et. al. (2008) 
provides more evidence of other potential uses for the drug Riluzole, that has originally been 
used for ALS, in neuropsychiatric illnesses. Banasr et. al. (2008) particularly investigated the 
role Riluzole could play in treating major depressive disorder (MDD) by studying glial 
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pathology. Glial pathology was the focus because there was growing research supporting that 
abnormalities and changes in glial functions are involved in the neuropathology of illnesses like 
MDD. Previous studies have found reduced glial cells and altered morphology in different parts 
of the brain but specifically in the prefrontal cortex. There has been suspect that this could be 
caused by exposure to chronic stress as seen in an animal model where, after exposure, they had 
both less glial density and less glial production in the hippocampus and prefrontal cortex (Banasr 
et. al., 2008). In turn, the impaired glial function is thought to lead to increased glutamatergic 
activation which has been shown to produce neurotoxic-like effects and we know Riluzole is a 
glutamate inhibitor by decreasing the presynaptic release and creating uptake. They hypothesize 
that the increased levels of Glu (glutamate) could relate to depressive behaviors and thus the 
uptake of Glu could create protective properties with antidepressant-like effects. Research 
conducted by Banasr et. al. (2008) found that chronic Riluzole treatment did either reverse or 
block the cellular and behavioral effects induced by chronic unpredictable stress (CUS) as well 
as reverse the decreased C-acetate metabolism and glial fibrillary acid protein (GFAP) 
expression that were also caused by CUS. “At a cellular level, chronic Riluzole treatment 
increased GLT-1 mRNA expression in the PFC (Banasr et. al., 2008).” Overall, the chronic 
Riluzole treatment was believed to have antidepressant properties especially to symptoms 
common in MDD specifically. Riluzole reversed several changes caused by CUS including glial 
cell AANt (amino acid nucleotides) metabolism, GFAP expression (key to cytoskeleton of 
astrocytes), and decreased Glu-C4, Gln-C4, and GABA-C2 that produce a depressive phenotype 
(Banasr et. al., 2008). Results of  Banasr et. al.’s (2008) study were unable to conclusively 
determine what pathophysiological mechanism connects stress, glial pathology, and behavior. 
However, their hypothesis was supported that that the pathophysiology of MDD is contributed to 
by AANt irregularities and glial cell pathology and that Riluzole can combat depressive 
BEHAVIORAL EFFECTS OF RILUZOLE 
 
53 
repercussions (Banasr et. al., 2008).  This is an interesting note in reference to more of 
psychological effects Riluzole can have and is a prominent area of research for Riluzole outside 
of its original purpose (Banasr et. al., 2008).  
 Riluzole has also become a key factor in studies for mental illness which is intriguing due 
to it being much less physically impairing and degenerating than a disease like ALS. However, 
the anxiolytic-like effects of Riluzole are similar to those of other treatments used for depression 
and mood disorders such as a benzodiazepine, specifically diazepam. Even with all the 
advancements in medicine and scientific research to date, the prevalence of mental illness 
remains astronomically high with few accurate medications on the market that do not come 
without properties of memory problems in particular. Hopefully this thesis work in addition to 
the limited scientific literature on Riluzole will lead to more individualized, or more effective 
treatments, with less side effects for the mentally ill.  
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Table 1. A list of over 20 of the genes that are possible contributions to ALS.  
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Figure 1. This figure demonstrates some of the etiology of ALS by examining the cellular processes 
that become dysfunctional; leading to various degenerative symptoms, a figure courtesy of Bartoletti et. 
al. (2019). The top box represents the genetic component that is affected in the body. TDP-43 is a 
binding protein for DNA and RNA and also helps  regulates further processes with RNA. FUS (fused in 
sarcoma) is another RNA binding protein (RBP) and often plays a role in the selective transport of 
mRNAs and their localization at synapses leading to synthesis (Bartoletti et al., 2019). C9orf72 
(chromosome 9 open reading frame 72) is a gene that details instructions for protein making primarily 
in the neurons of the cerebral cortex and motor neurons of the brain and spinal cord (Genetics Home 
Reference, 2016). SOD1 (superoxide dismutase-1) is one of the antioxidant enzymes responsible for 
gene encoding (Zarei et. al., 2015). The arrows from the top box point to the biological processes, in the 
second box, that are disrupted when there is a misfolding, repeating sequence, or any mutation of these 
genetic factors. The third box represents possible therapeutic targets to counteract the affected processes 
of the second box. The fourth box represents the symptoms that will be reduced when the possible 
therapeutic approaches are used in relation to the genetic factor that is identified as dysfunctional.  
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Figure 2. The chemical structure of Riluzole represented in a two-dimensional (top) and 3-dimensional 
(bottom) perspective. The trade name of this drug is Rilutek however, its generic name Riluzole is typically 
used. It is a member of the benzothiazole class. Its molecular formula is read as C8H5F3N2OS and weighs 
234.2 g/mol. The physical properties appear as a white to slightly yellow powder that is available as a 
white, film coated capsule to take orally (Food and Drug Administration, 2016). Images retrieved from 
National Center for Biotechnology Information. PubChem Database. 
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Figure 6a. shows the amount of time in seconds the low, moderate, and high Riluzole 
dosed Tx groups, compared to the control group, ran on the Rotorod apparatus 90 minutes 
after their third set of injections demonstrating their level of coordination post injection. 
Figure 6b. shows how far, in meters, the mice traveled on the Rotorod on a low, 
moderate, and high dose of Riluzole, compared to the control group, 90 minutes after their 
third and final injection period to demonstrate the level of endurance in the mice and 
assess for any fatigue post injection. Any asterisks in Figure 6 signify the finding of 
statistically significant results.   
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Figure 7. Shows the coordination of mice represented by the elapsed time, in seconds, spent 
running on the Rotorod after one week of Tx (7a.), two weeks of Tx (7b.), and three weeks 
of Tx (7c), after a control, low, moderate, and high dosage administration and observed over 
the course of 9 time intervals after injection.  
 
